GlassScriptPhysician profile
Mary A Lim Lee
NPI 1649240136
$1,332.52
in general payments reported to CMS, 2019-2025
27 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $82.12 · 2021: $287 · 2022: $241 · 2023: $379 · 2024: $15.90 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.19 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $162.58 | 2019-2023 | |
| Abbott Laboratories | $137.77 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $119.51 | 2020-2023 | Mounjaro |
| Abbvie INC. | $115.59 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.93 | 2023 | Austedo Xr |
| Amgen INC. | $66.99 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.14 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $40.30 | 2019 | |
| Exact Sciences Corporation | $38.26 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $35.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.51 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $24.81 | 2020-2022 | |
| Axsome Therapeutics, INC. | $18.23 | 2023 | Auvelity |
| Octapharma USA, INC. | $18.20 | 2025 | Fibryga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $17.38 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Nestle Healthcare Nutrition INC. | $16.70 | 2021 | |
| Eisai INC. | $16.47 | 2021 | |
| Corcept Therapeutics | $15.80 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $15.58 | 2021 | |
| Daiichi Sankyo INC. | $14.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.90 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.73 | 2023 | Rexulti |
| Allergan, INC. | $13.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.06 | 2020 | |
| Amarin Pharma, INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lim Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.